I know it's early days so there may not be much information. The prices in the US for private use are as follows:
0.8 mg (Starting dose): ~$149 per month.
2.5 mg: ~$199 per month.
5.5 mg / 9 mg: ~$299 per month.
14.5 mg / 17.2 mg: ~$299–$349 per month.
Any idea or guesses what the prices will look like here for us?
I have a feeling (only gut, no evidence) that we are going to see the Mounjaro community stop buying new pens from now, hoping to use up stockpiles just in time for the release of FD (Foundayo). This sudden drop in MJ sales could then potentially kickstart a massive drive from pharmacies to try and get rid of their stocks too. We might see big sales and incentives in the near future as we get closer to MHRA Approval.......Again, just a thought I had.
From the drugs.com website (How much does Foundayo cost?) suggesting that 5.5 & 9mg are considered 'higher maintenance doses'.
I need to dig deeper to better understand the clinical basis for this...
Foundayo costs:
So, which one would you choose?
Here's the info:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11650/documents
Patient Expert Expression of Interest – NICE Technology Appraisal for a new treatment for people living with a higher weight
Activity description:
NICE is evaluating whether a new medicine is suitable for use across the NHS. Orforglipron is a once‑daily tablet designed to support people living with higher weight. It works by reducing appetite and increasing feelings of fullness, helping some people eat less without feeling as hungry. It belongs to the same group of medicines as other GLP‑1 treatments (medicines that help regulate appetite, blood sugar, and digestion) but is taken as a tablet rather than an injection. This appraisal focuses on people living with higher weight who also have at least one weight‑related health condition (sometimes called a co‑morbidity), such as high blood pressure, type 2 diabetes, joint problems, or other long‑term health conditions.
We are looking for patient experts who can help the NICE committee understand the lived experience of people living with a higher weight, and what matters most to patients and carers when considering treatments like this.
You can read more about the Orforglipron for managing overweight and obesity appraisal (if you click on the ‘Project documents’ tab towards the top right hand side of the webpage, you’ll also find documents like the scope which tell you more about the plans for this guidance).
Skills & Experience Needed:
We welcome expressions of interest from people with lived experience of living with a higher weight, including where this is alongside one or more weight‑related health conditions, either as a patient or a carer. You do not need to have experience with the specific drug being appraised (Orforglipron). You will need to feel comfortable sharing your experience and views in a large meeting. Support and guidance will be provided if you are selected, including an induction before the committee meeting.
Time Commitment:
Completing a nomination form by Wednesday 22 April and, if selected, then also a personal statement (guidance provided on how to do this)
A 1-hour pre-meeting induction (briefing) on Wednesday 20 May at 4.30pm
Reading background papers in the week before the committee meeting
Attending the committee meeting (approx. 3 hours) on Tuesday 14 July 2026
Key Date: Tuesday 14 July 2026 (committee meeting date)
Location: Both meetings will take place virtually, via Zoom.
Payment: The committee meeting payment will be £75 for up to and including 4 hours. The pre-briefing meeting payment will be £75.
How to Express an Interest: Please email Charlotte Stephens and Jessica Bailey (Public Involvement Advisor) to express your interest or to ask any questions
(Please quote : NICE ID "ID6516" in the title of your email. You will be asked to complete a nomination form outlining your experience by Wednesday 22 April – we will provide you with guidance on how to do this)
How Members Will Be Selected: The Chair of the committee will review all nomination forms and then select the most appropriate patient expert for the topic.
Closing date: 09.00, Monday 20 April 2026
